Yonalink has raised $6m in a funding round to scale growth worldwide and also expand the capabilities of its EHR-to-EDC integration platform designed to stream clinical trial data.

By exporting patient data from a clinical site’s EHR system directly, YonaLink’s software as a service (SaaS) platform transfers it into clinical research electronic data capture (EDC) systems.

This solution has been purpose-built for streaming and mapping up-to-date data of participants, in real time.

It also provides the missing link in data collection during trials, and automates real-time patient data securely from EHRs.

The funding round was led by the Debiopharm Innovation Fund in Switzerland and co-funded by the European Union. It also saw participation from Israel’s eHealth Ventures .

YonaLink will also use the investment for driving its adoption among sponsors of clinical trials and their clinical research organisation (CRO) partners.

YonaLink CEO and co-founder Iddo Peleg said: “YonaLink is bridging the gap between patient care and clinical research, providing the missing link in clinical trial data collection and validation with technology that securely provides true EHR-to-EDC connectivity, without disrupting existing clinical trial workflows.

“We’re excited to bring our technology to more clinical trials, beginning with the US, Europe, and Israel, to help fuel innovation in clinical development and accelerate the delivery of important new treatments to patients across disease states and therapeutic areas.”

The platform can also stream up-to-date data from the EHR system of any clinical site in any part of the world and populate it within YonaLink’s other data capture systems or EDC.

YonaLink’s EDC has built-in eConsent and ePRO/ eCOA and streaming EHR-to-EDC capabilities and provides a comprehensive solution for clinical trial needs.

eHealth Ventures partner Ophir Shahaf said: “YonaLink is changing the paradigm with a solution that provides true automation. This technology can be used to help reduce the burden on research sites, lower trial costs, and enable efficiencies that speed time to market for clinical trial sponsors.”